Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
US Army
Fish and Richardson
UBS
Accenture
Boehringer Ingelheim
McKesson
Covington
Cipla

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,586,458

« Back to Dashboard

Which drugs does patent 6,586,458 protect, and when does it expire?

Patent 6,586,458 protects TREXIMET and is included in one NDA.

Protection for TREXIMET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in eleven countries.
Summary for Patent: 6,586,458
Title: Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Abstract:The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT agonist. Included among the long-acting NSAIDs are cyclo-oxygenase-2 inhibitors.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen Inc. (Chapel Hill, NC)
Application Number:09/559,753
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition; Delivery;

Drugs Protected by US Patent 6,586,458

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,586,458

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,872,145 Formulation of 5-HT agonist and NSAID for treatment of migraine ➤ Subscribe
6,060,499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs ➤ Subscribe
8,022,095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,586,458

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 286393 ➤ Subscribe
Australia 3596500 ➤ Subscribe
Australia 3984597 ➤ Subscribe
Australia 711741 ➤ Subscribe
Canada 2260943 ➤ Subscribe
Germany 69732189 ➤ Subscribe
Denmark 0957914 ➤ Subscribe
European Patent Office 0957914 ➤ Subscribe
Spain 2234025 ➤ Subscribe
Hong Kong 1023517 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Colorcon
Dow
Merck
Chinese Patent Office
AstraZeneca
Queensland Health
US Army
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot